Ipamorelin

Purity: >98% (HPLC on request) | Molecular Formula: C38H49N905
Molecular Weight: 711.863 | Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH

Content & Potency: 2000mcg/ml subcutaneous injectable provided in a 5ml vial.

“Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers To examine the pharmacokinetics (PK) and decline to negligible GH concentration at all doses.
The pharmacodynamics (PD) of ipamorelin, a growth hormone ipamorelin-GH concentration relationship was (GH) releasing peptide, in healthy volunteers. A trial was characterized using an indirect response model and conducted with a dose escalation design comprising 5 population fitting.
The model employed a zero-order GH different infusion rates (4.21, 14.02, 42.13, 84.27 and release rate over a finite duration of time to describe the 140.45 nmol/kg over 15 minutes) with eight healthy male episodic release of GH. Ipamorelin induces the release subjects at each dose level. Concentrations of ipamorelin of GH at all dose levels with the concentration (SC50) and growth hormone were measured. The PK parameters required for half-maximal GH stimulation of 214 nmol/ showed dose-proportionality, with a short terminal half-life Land a maximal GH production rate of 694 mlU/L/h. of 2 hours, a clearance of 0.078 L/h/kg and a volume of The inter-individual variability of the PD parameters was distribution at steady-state of 0.22 L/kg. The time course larger than that of the PK parameters.
The proposed PK/ of GH stimulation by ipamorelin showed a single episode PD model provides a useful characterization of ipamorelin of GH release with a peak at 0.67 hours and an exponential disposition and GH responses across a range of doses.
Gobburu, Jogarao & Agerso, Henrik & ). Jusko, William & Ynddal, Lars. (1999). Pharmacokinetic- Pharmacodynamic Modeling of Ipamorelin, a Growch Hormone Releasing Peptide, in Human Volunteers, Pharmaceutical research. 16. 1412-6.”